Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 19,375 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 19,375 shares of the business’s stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25. Following the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at $12,438,989.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25.
• On Wednesday, September 11th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.50, for a total value of $585,937.50.
• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The stock was sold at an average price of $39.76, for a total value of $575,366.96.

Vera Therapeutics Stock Up 3.3 %

VERA stock opened at $41.09 on Monday. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 52 week low of $9.68 and a 52 week high of $50.78. The stock has a market capitalization of $2.25 billion, a PE ratio of -20.04 and a beta of 1.00. The firm has a 50 day moving average of $40.18 and a 200 day moving average of $38.94.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on VERA. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Scotiabank started coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target for the company. Finally, Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $52.67.

Institutional Trading of Vera Therapeutics

Several large investors have recently added to or reduced their stakes in the company. William Marsh Rice University purchased a new stake in Vera Therapeutics in the second quarter valued at approximately $593,000. Cambridge Trust Co. lifted its stake in Vera Therapeutics by 386.6% during the 1st quarter. Cambridge Trust Co. now owns 48,107 shares of the company’s stock valued at $2,074,000 after acquiring an additional 38,220 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Vera Therapeutics in the 1st quarter valued at $9,727,000. Renaissance Technologies LLC increased its stake in shares of Vera Therapeutics by 28.5% in the second quarter. Renaissance Technologies LLC now owns 147,800 shares of the company’s stock worth $5,347,000 after acquiring an additional 32,800 shares during the period. Finally, Jennison Associates LLC purchased a new position in shares of Vera Therapeutics during the first quarter worth $3,231,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.